Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Pharmaceutical Statistics|February 17, 2021
Statistical considerations in clinical trial design with event-free survival as the primary efficacy endpointTu Xu, Yiming Zhang, Meredith Goldwasser, et al.Journal of Biopharmaceutical Statistics|February 8, 2023
Recent Use of Pediatric Extrapolation in Pediatric Drug Development in USJingjing Ye, Vickie Zhang, Foteini Strimenopoulou, et al.Magnetic Resonance Imaging|May 16, 2008
Feasibility of using hyperpolarized [1-13C]lactate as a substrate for in vivo metabolic 13C MRSI studiesAlbert P Chen, John Kurhanewicz, Robert Bok, et al.Environmental Science & Technology|April 19, 2011
High postnatal exposures to polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs) via breast milk in California: does BDE-209 transfer to breast milk?June-soo Park, Jianwen She, Arthur Holden, et al.Journal of Magnetic Resonance (San Diego, Calif. : 1997)|November 4, 2009
Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP miceMatthew L Zierhut, Yi-Fen Yen, Albert P Chen, et al.International Journal of Radiation Oncology, Biology, Physics|April 28, 2020
Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized 13C MRI Can Evaluate Early and Dose-Dependent Response to Radiation Therapy in a Prostate Cancer Mouse ModelHecong Qin, Vickie Zhang, Robert A Bok, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaCourtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.The New England Journal of Medicine|June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLCourtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.Pageof 1